Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhancing care for people living with HIV: current and future monitoring approaches.
Maggiolo F, Bandera A, Bonora S, Borderi M, Calcagno A, Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A. Maggiolo F, et al. Among authors: bonora s. Expert Rev Anti Infect Ther. 2021 Apr;19(4):443-456. doi: 10.1080/14787210.2021.1823217. Epub 2020 Oct 15. Expert Rev Anti Infect Ther. 2021. PMID: 33054479 Free article. Review.
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.
Carosi G, Puoti M, Antonucci G, De Luca A, Maserati R, Torti C, Bonfanti P, Bonora S, Bruno R, Gaeta GB, Antinori A, Monforte Ad, Orani A, Sagnelli E, Cargnel A, Cauda R, Mazzotta F, Pastore G, Suter F, Vullo V; Italian ART; HCV-HIV Coinfection Working Group. Carosi G, et al. Among authors: bonora s. AIDS Rev. 2005 Jul-Sep;7(3):161-7. AIDS Rev. 2005. PMID: 16302464
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
González de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. González de Requena D, et al. Among authors: bonora s. AIDS. 2006 Oct 3;20(15):1977-9. doi: 10.1097/01.aids.0000247121.19951.fa. AIDS. 2006. PMID: 16988521
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. de Requena DG, et al. Among authors: bonora s. Antimicrob Agents Chemother. 2008 Mar;52(3):1066-71. doi: 10.1128/AAC.01063-07. Epub 2007 Dec 26. Antimicrob Agents Chemother. 2008. PMID: 18160524 Free PMC article.
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
Svicher V, Alteri C, D'Arrigo R, Laganà A, Trignetti M, Lo Caputo S, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, di Perri G, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Svicher V, et al. Among authors: bonora s. Antimicrob Agents Chemother. 2009 Jul;53(7):2816-23. doi: 10.1128/AAC.01067-08. Epub 2009 Jan 5. Antimicrob Agents Chemother. 2009. PMID: 19124665 Free PMC article.
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.
Saracino A, Monno L, Tartaglia A, Tinelli C, Seminari E, Maggiolo F, Bonora S, Rusconi S, Micheli V, Lo Caputo S, Lazzaroni L, Ferrara S, Ladisa N, Nasta P, Parruti G, Bellagamba R, Forbici F, Angarano G. Saracino A, et al. Among authors: bonora s. Curr HIV Res. 2009 Jul;7(4):425-33. doi: 10.2174/157016209788680525. Curr HIV Res. 2009. PMID: 19601778 Free article.
[HIV infection: treatment of naive patients].
Bonora S, Calcagno A, Di Perri G. Bonora S, et al. Infez Med. 2009 Jun;17(2):69-81. Infez Med. 2009. PMID: 19602919 Free article. Review. Italian.
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
496 results